

9/762376

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
DESIGNATED/ELECTED OFFICE (DO/EO/US)CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that this RESPONSE and the documents referred to as enclosed therein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service Express Mail Label No. **EL587948871US** under 37 CFR §1.10, on the date indicated below and is addressed to: Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

Nancy Barker

Nancy Barker

10/19/01

Date of Deposit

Applicant: Wong, et al.)
U.S. Serial No.: 09/762,376)
International Application No.: PCT/US99/18154) Art Unit No.: Unassigned
International Filing Date: August 10, 1999) Examiner: Unassigned
Title: α 2,8/2,9 POLYSIALYLTRANSFERASE) Our Ref. No.: TSRI 663.1
)
)
)

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
UNDER 35 U.S.C. 371 IN THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)

Assistant Commissioner for Patents
Washington, D.C. 20231
ATTN: BOX PCT

Dear Sir:

In response to the enclosed copy of the PTO Communication regarding the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed August 10, 2001, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled

T000220-9173294260

663.1/OPT 0022P.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

By Donald G. Lewis
Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937